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Metabolic associated fatty liver disease (MAFLD) encompasses a broad spectrum of hepatic disorders, which
include steatosis, nonalcoholic steatohepatitis (NASH), fibrosis and cirrhosis, that is a critical risk factor for
hepatocellular carcinoma (HCC) development. Its pathogenesis is intertwined with obesity and type 2 diabe-
tes (T2D). However, the predisposition to develop MAFLD is severely influenced by environmental and inher-
ited cues. The rs641738 variant close to MBOAT7 gene has been identified by a genome-wide association
screening in heavy drinkers. Although this variant has been associated with the entire spectrum of MAFLD,
these results have not been completely replicated and the debate is still opened. Thus, functional studies that
unravel the biological mechanisms underlying the genetic association with fatty liver are required. This
review aims to summarize the clinical and experimental findings regarding the rs641738 variation and
MBOAT7 function, with the purpose to shed light to its role as novel player in MAFLD pathophysiology.
© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
MBOAT7
LPIAT1
MAFLD
NASH
Hyperinsulinemia
Insulin resistance
PhospholipidsP. Dongiovanni).
B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)1. Introduction
Nonalcoholic or more recently re-defined Metabolic associated
fatty liver disease (MAFLD) is the most common chronic liver disor-
der worldwide, affecting more than one third of the general popula-
tion (around 30% of adults in industrialized countries) [1, 2]. Thus,
given its increasing proportion, it represents a primary health, social
and economic concern [3]. MAFLD is defined by enhanced hepatic fat
deposition that exceeds 5% of liver weight, in absence of alcohol
abuse and it entails a wide spectrum of hepatic clinical conditions,
spanning from uncomplicated steatosis to nonalcoholic steatohepati-
tis (NASH), defined by the presence of lobular inflammation and
hepatocyte ballooning, to fibrosis, cirrhosis and, only in a minor per-
centage of cases, to hepatocellular carcinoma (HCC) [4].
MAFLD is epidemiologically related to obesity, type 2 diabetes
(T2D) and metabolic syndrome (MetS) [5] and its pathogenesis is
closely entangled with increased adiposity, insulin resistance (IR)
and dyslipidemia [6]. Indeed, it is regarded as the hepatic manifesta-
tion of MetS and its prevalence increases along with body mass index
(BMI), reaching 6070% in obese patients [7]. The risk of progressive
MAFLD is higher in patients with severe hyperinsulinemia, IR and
T2D, which are identified as the strongest predictors of advancedfibrosis and cirrhosis. Therefore, the prevalence of MAFLD in T2D
patients is estimated at 3474% and it is even higher in T2D patients
with obesity (almost 100%) [8]. As a consequence, unhealthy dietary
habits, excessive caloric intake, high fructose consumption and poor
physical exercise greatly contribute to this pathological condition [9].
Nonetheless, the inter-individual predisposition to develop
MAFLD may be also attributable to inherited factors [10]. Single
nucleotide polymorphisms (SNPs) in genes regulating hepatic lipid
remodeling, among which Patatin-like Phospholipase Domain-contain-
ing 3 (PNPLA3), Transmembrane 6 Superfamily Member 2 (TM6SF2) and
Membrane Bound O-acyltransferase Domain-containing 7 (MBOAT7),
have been broadly associated with increased susceptibility to develop
the entire spectrum of MAFLD from steatosis towards NASH and
fibrosis [11]. The unraveling of the biological associations between
fatty liver and inherited risk factors, and their interplay with environ-
mental context are primary goals in the study of MAFLD pathophysi-
ology. More deeply, the mechanism whereby the less explored
MBOAT7 variations exert detrimental effects at hepatic level remains
to be fully elucidated.
Currently, no therapeutic consensus exists for the treatment of
MAFLD and lifestyle modifications, regular physical activity and sus-
tained weight loss remain the cornerstone of approaches to patients
with MAFLD, with the purpose to improve glycemic control, hepatic
insulin sensitivity, liver enzymes and histology [12]. However,
mounting evidence points out that the individual genetic background
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approaches [9].
Therefore, this review pursuits to highlight recent findings about
the role of MBOAT7 regulation in hyperinsulinemia and IR as a novel
example of the gene-environment interaction. These concepts pave
the way to improve our knowledge about the mechanisms that pre-
dispose to steatosis during IR and emphasize the idea to target
MBOAT7 for therapeutic strategies.2. Insulin resistance and MAFLD pathogenesis
Although the precise mechanism of MAFLD pathogenesis is still
under definition, current knowledge supports a model whereby the
development of liver injury is multifactorial, commonly referred to as
the ‘multi-hits’ hypothesis [1316]. In particular, IR is accountable for
the ‘first hit’ that induces the rising of hepatic steatosis.
IR is defined as a pathological condition in which physiological or
elevated insulin concentrations produce an attenuated biological
response, mainly in terms of glucose homeostasis [17]. IR may be due
to either impaired insulin receptor activity and/or expression or to a
derangement in insulin response through the downstream signaling
cascades, or less frequently to loss-of-function mutations in Insulin
receptor (INSR) gene. In obese subjects, IR results in chronically ele-
vated insulin concentrations (hyperinsulinemia), alterations in insu-
lin secretion and clearance, increased glucose output and decreased
hepatic glucose utilization [18]. To compensate the dampened insulin
sensitivity, pancreatic b-cells over-produce insulin, eventually
undergoing to exhaustion and leading to impaired glucose tolerance
and T2D [19]. Furthermore, in IR context, insulin fails to inactivate
gluconeogenesis [20].
In muscle and adipose tissue, IR determines an impairment of glu-
cose uptake and promotes an enhanced activity of hormone-sensitive
lipoprotein lipases, favoring lipid storage dismissal [21]. Therefore, in
MAFLD patients, it is well supported that hepatic fat accumulation
results from an increased efflux of non-esterified or free fatty acids
(FFAs) from adipose tissue to the liver where they are stored into the
hepatocytes as triglycerides (TAG), in order to protect cells from lipo-
toxicity [22]. In addition, hyperinsulinemia exacerbates fat depot for-
mation, by inducing de novo lipogenesis from glucose through sterol
regulatory element-binding protein-1c (SREBP-1c). Reduction in neu-
tral lipid secretion through very low-density lipoproteins (VLDL) and
in b-oxidation due to mitochondrial dysfunction are also involved in
steatosis onset [23]. In turn, fatty liver per se may then precipitate
hepatic IR promoting metabolic disturbances and cardiovascular
damage [24]. Lipid metabolites, such as diacylglycerols (DAG), ceram-
ides and long chain acyl-CoA have also been implicated in IR, affect-
ing insulin signaling [25]. Thus, the composition of lipid species and
the tight regulation of the phospholipid distribution in plasmatic and
organelle membranes is extremely essential to maintain the physio-
logical signal transduction, the adequate response to insulin and the
exchange of metabolites from membranes to intracellular compart-
ments [26, 27]. These notions suggest that alteration in intracellular
lipid profiles may further contribute to fatty liver [28]. Indeed, grow-
ing evidence indicates that changes in polyunsaturated fatty acids
(PUFAs) play a crucial role in MAFLD onset. In particular, it has been
observed that arachidonic acid and eicosapentanoic acid-related spe-
cies decreased in the liver of MAFLD patients, supporting a reduction
of enzymatic activity of desaturases [28].
Modifications in lipid homeostasis play also a role in the cascade
of events that may precipitate fatty liver to NASH. In particular,
arachidonic acid is released from the phospholipids of the mem-
branes by phospholipase A2, that is extremely enhanced in NASH
patients. The utilization of arachidonic acid by cyclooxygenases may
also contribute to its reduction observed in NASH patients and to its
conversion into proinflammatory prostaglandins, thromboxanes, andleukotrienes [28]. Thus, lipids are intertwined with inflammatory
pathways and cellular injuries in NASH [29].3. The rs641738 variant is considered a risk factor for MAFLD
onset and progression
MAFLD has a strong inherited component and several genetic risk
factors are recognized to influence its onset and severity, as broadly
revealed by epidemiological, familial and twin studies [3032].
Indeed, the individual susceptibility to develop MAFLD is striking
diverse among subjects characterized by the same adiposity, support-
ing the notion that the genetic make-up contributes to the pheno-
typic variability of MAFLD. In particular, hepatic fat accumulation
which is epidemiologically related to IR and MetS, has been indicated
as the main driver of the progression to end-stage liver injuries in
genetically predisposed individuals. Thus, the effect of each genetic
variation on the spectrum of MAFLD is closely intertwined with their
ability to induce fat accumulation [33].
In 2015, the first genome-wide association study (GWAS), regard-
ing the inherited determinants of alcoholic cirrhosis in heavy
drinkers, identified the common rs641738 C>T variant as a novel
mediator of the susceptibility to develop hepatic damage [34, 35].
This naturally occurring variation is localized in the Membrane bound
o-acyltransferase domain-containing 7  Transmembrane channel-like
4 (MBOAT7-TMC4) locus on chromosome 19 [34]. Mancina and Don-
giovanni further corroborated these findings, demonstrating that the
rs641738 variant associates with steatosis severity and with the
entire spectrum of liver damage related to MAFLD, including HCC
[3638]. Their observations were well supported since they analyzed
the rs641738 distribution among two different independent cohorts,
the Dallas Heart study (DHS) cohort and the Liver biopsy cross-sec-
tional cohort (LBC). The former is a population-study that includes
3854 individuals of whom 2736 underwent to proton magnetic reso-
nance spectroscopy to measure hepatic TAG content, whereas the lat-
ter entails 1149 European subjects, who underwent liver biopsy for
suspected NASH or severe obesity. Patients carrying the T allele dis-
played an enhanced TAG content, higher prevalence of NASH and
fibrosis compared to non-carriers [36]. This data has been even con-
firmed in a cohort of pediatric individuals in whichMBOAT7 variation
correlated with high circulating liver enzymes, mainly ALT levels and
C-reactive protein (CRP) concentrations, and with increased total
body fat percentage [39]. These results may introduce the concept
that MBOAT7 might regulate not only hepatic fat accumulation but
also the whole body adiposity [39, 40]. In 2018, Di Sessa and collabo-
rators supported this evidence, revealing that T allele carriers were
characterized by high ALT, more advanced steatosis and fibrosis in
1002 obese pediatric patients. Moreover, they found a combined
effect of the rs641738, PNPLA3 I148M, and TM6SF2 E167K variants on
pediatric MAFLD risk [41]. This combined effect has been previously
investigated in a multicenter biopsy-based study by Krawczyk and
colleagues, revealing that the co-presence of the three main risk var-
iants correlates with more advanced liver injury in adult MAFLD
patients, testified by a severe enhancement of circulating liver
enzymes [42]. Thus, score-based strategies on the evaluation of poly-
genic determinants of MAFLD are considered highly predictive and
they can be exploited to improve diagnostic accuracy and to guide
treatment options [43, 44].
Notably, the rs641738 variant has been identified as a risk factor
for the transition to early fibrosis in viral hepatitis B (HBV) and C
(HCV), possibly representing a common modifier of liver damage [45,
46]. Moreover, it predisposes to HCC development, even in the
absence of cirrhosis in 765 patients with MAFLD and in 1121 non-cir-
rhotic patients affected by HCV or alcoholic liver disease (ALD) [38].
Even more, rare loss-of-function variants inMBOAT7 have been found
to be associated with HCC in NAFLD patients [47]. Nonetheless, it has
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effect on transplant free survival [48, 49].
However, the association between the rs641738 variant and liver
injuries remains still controversial and not fully replicated, mainly due
to the different sample size, clinical features and severity of the disease
(i.e. obesity and T2D presence), and ethnicity of the cohorts enrolled in
the studies or to the diverse assessment of hepatic steatosis [5054].
In particular, the T allele frequency in different ethnicity is highly vari-
able ranging from 0.44 in Europeans, 0.32 in African-Americans and
0.34 in Hispanics and displays even intra-ethnic variability (0.24 in
East Asians compared to 0.53 in those of South Asian ancestry). For
example, the loss of association between the rs641738 variant and
hepatic steatosis assessed by ultrasonography has been observed in
831 Taiwanese children by Lin YC and coworkers [55]. Moreover, for
complex diseases, an interplay between genetics and environmental
factors exists and geneenvironment interactions may amplify the
phenotypic effects of the inherited variations [56]. Indeed, the associa-
tions between common variants and MAFLD may be unmasked by the
increased adiposity, thus enhancing the genetic risk [56]. Thus, we
could speculated that in cohort in which the obesity rate is low among
NAFLD patients, the association between the rs641738 variant and
NAFLD did not obtained a statistical significance [54].
Therefore, a large meta-analysis is required to deeply elucidate
the role of this variation on the spectrum of MAFLD. Very recent
results which have been obtained by considering data from 1047,265
participants, of whom 8303 had liver biopsies, across 42 studies, con-
firmed the positive correlation between the rs641738 variant and
liver fat, ALT, histological severity of MAFLD, fibrosis and HCC in indi-
viduals of European descent [57]. In particular, it has been reported
that in T allele carriers, the total risk of NAFLD, advanced fibrosis and
HCC is attested at 20%, 30% and 40% more compared to non-carriers,
respectively. Thus, the effect sizes reported for the MBOAT7
rs641738 variant is smaller compared to the ones of PNPLA3 I148M
and TM6SF2 E167K. Likewise, functional studies are required to
extensively explain the mechanisms through which the presence of
the rs641738 variant may favor hepatic fat accumulation and pro-
gressive liver damage.
Although NAFLD pathogenesis is closely entangled with metabolic
syndrome features among which atherogenic dyslipidemia and car-
diovascular disease risk, it remains unclear whether the rs641738
variant may exert an impact on cardiovascular diseases [58, 59].
Indeed, while it is well described that the PNPLA3 I148M and the
TM6SF2 E167K variants play a protective role against coronary artery
disease (CAD), the rs641738 T allele seems to have a neutral effect,
but this association remains poorly explored and further studies are
necessary to validate these findings [60]. Moreover, the MBOAT7
rs8736 C>T variant located in the 30 UTR has been associated with
cardiovascular outcomes and TT carriers showed significantly
reduced levels of PI (18:0;020:4;0) reinforcing the concept of a cor-
relation between genetic factors and lipid species composition [61].
The main studies that explored the association between the
rs641738 and liver damage have been listed in Table 1.
4. MBOAT7 function
MBOAT7 gene is the mammalian orthologue of mboa-7, that has
been firstly identified by using a RNA interferencebased genetic
screen in Caenorhabditis elegans [62]. mboa-7 deletion mutants
showed a decreased Eicosapentaenoic acid (EPA), that is the predom-
inant PUFA in C. elegans, reduced phosphatidylinositol species (PI)
[62] and impaired PI-3-phosphate (PI3P)-related events such as early
endosome morphology and autophagy [63]. Thus, these findings
revealed thatmboa-7, is required for incorporation of PUFAs into PI.
MBOAT7 is also referred to as Lysophosphatidyl-inositol acyltrans-
ferase 1 (LPIAT1). MBOAT7 gene codifies for an enzyme, member of
the “Lands’ Cycle” of phospholipid acyl-chain remodeling of themembranes, through sequential deacylation and reacylation reac-
tions. It catalyzes a desaturation of the second acyl-chain of phospho-
lipids and specifically transfers a PUFA, in form of acyl-CoA to lysoPI
and other lysophospholipids, using as preferential substrate the
arachidonoyl-CoA. Thus, it is a fine-tune regulator of the amount of
free arachidonic acid, that, as mentioned above, is a potent trigger for
hepatic inflammation and fibrosis, due to its conversion in eicosa-
noids [64]. Indeed, in neutrophils MBOAT7 activation has been found
to be related to anti-inflammatory processes, by limiting the avail-
ability of free arachidonic acid for the synthesis of Leukotriene B4,
that is a strong chemoattractant mediator [65].
It has been deeply investigated that Mboat7 participates to brain
development in mice, since arachidonic acid is the most enriched
PUFA in the brain and it is involved in multiple aspects of neuronal
development and function. Mboat7 knock-out (KO) mice show
almost no activity with arachidonoyl-CoA as an acyl donor and show
reduced arachidonic acid contents in PI and PI phosphates (PIP, PIP2
and PI3P). Specifically, arachidonic acid-containing PI/PI phosphates
play an important role in normal cortical lamination during brain
development in mice. Indeed, Mboat7 KO mice die within a month
and show atrophy of the cerebral cortex and hippocampus, disor-
dered cortical lamination and neuronal processes and delayed neuro-
nal migration in the cortex [63,66]. Notably, inactivating variants in
MBOAT7 lead to intellectual disability accompanied by epilepsy and
autistic features in patients [67,68]. In turn, up-regulation of MBOAT7
in intrauterine growth restriction (IUGR) neonates could represent
an adaptive response to an adverse fetal environment [67].
PI are enabled to regulate membrane dynamics and signal trans-
duction pathways, whereas PI phosphates are synthesized by PI kin-
ases and phosphatases and play crucial roles in the regulation of a
wide variety of cellular processes via specific interactions of PIP-bind-
ing proteins [69,70]. Among PI phosphates, PI 3-phosphate (PI3P)
regulates vesicular trafficking pathways, including endocytosis,
endosome-to-Golgi retrograde transport, autophagy and mTOR sig-
naling [71]. Therefore, given its regulatory role in lipid composition
of the membranes, we could speculate that MBOAT7 function might
also influence signal transduction pathways and the dynamism of
cell membranes, essential for membrane fusion and fission steps dur-
ing endocytosis, exocytosis, cytokinesis and vesicle trafficking.
At a cellular level, the highest expression of MBOAT7 is found in
circulating monocytes and lymphocytes, which it has been attested
at 7-fold more than that of human hepatocytes, sinusoidal endothe-
lial cells and HSCs. Conversely, its expression in cholangiocytes is
very low [38, 49, 72]. MBOAT7 topological structure has been
recently solved by Caddeo at al, which demonstrated that is a multi-
spanning integral membrane protein with 6 transmembrane
domains and the putative catalytic dyad in the lumen [73]. It is local-
ized specifically in membrane fractions rich in phospholipids, such as
the ER and the mitochondria-associated membranes (MAM), where
arachidonic acid-selective acyl-CoA synthases are enriched [36].
MAM is the membrane bridging ER and mitochondria, which is
involved in the biosynthesis and trafficking of lipids between the two
organelles [74, 75] and in lipid droplets formation [76]. It interacts
with the small subunit of serine palmitoyltransferase a (ssSPTa), that
plays a role in fatty acid remodeling of PI, probably by facilitating
MBOAT7 localization in MAM [77].
Another enzyme of the MBOAT family, MBOAT5 (mammalian
orthologue ofmboa-6 [78]), also named Lysophosphatidylcholine acyl-
transferase 3 (LPCAT3), has similar enzymatic activity to MBOAT7. It is
ubiquitously expressed, especially in liver, testis, kidney, pancreas and
adipose tissue, where it participates in the acyl-chain remodeling of
Phosphatidylcholines (PC), Phosphatidylserine (PS) and Phosphatidyle-
thanolamines (PE) [79]. Expression of LPCAT3 mRNA is controlled by
liver X receptors (LXR) and is induced during adipogenesis [80].
Mboat5 KO mice are neonatally lethal due to an extensive TAG accu-
mulation in enterocytes since TAG are not assembled into lipoproteins.
Table 1
List of studies that explored the association between the rs641738 and liver damage.
First author, year, reference Country, Ancestry Study Type Sample size, features Liver disease diagnosis Associations
Buch et al., 2015 [35] Caucasians GWAS Discovery: 712 cases and
1426 controls;
Validation: 1148 cases
and 922 controls
Liver biopsy, ultrasound
(US), MRI
Alcohol-related cirrhosis
Mancina and Dongiovanni
et al., 2016 [36]
Multi-ethnic Population-based (first
stage); cases only (second
stage)
3854 participants from the
DHS (first stage)
1149 cases from LBC (sec-
ond stage)
DHS: liver spectroscopy
(n = 2736);
LBC: liver biopsy
Steatosis, NASH, Fibrosis
stage
Luukkonen et al., 2016 [37] Caucasians Cases only 125 cases Liver biopsy Steatosis, NASH, Fibrosis
stage
Viitasalo et al., 2016 [39] Caucasians Population-based 467 children Not assessed Plasma ALT levels
Krawczyk et al., 2016 [40] Caucasians Cases only 84 obese individuals sched-
uled for bariatric surgery
Liver biopsy and MRI Circulating TAG, total cho-
lesterol, LDL, and serum
glucose levels
No evidence of association
with steatosis
Thabet et al., 2016 [46] Caucasians Case-control Discovery: 931 HCV cases;
270 controls
Validation: 765 HCV cases;
75 HCV-related HCC cases
Liver biopsy Hepatic inflammation and
fibrosis stage
Donati et al., 2017 [38] Caucasians Case-control 765 non-cirrhotic MAFLD
cases (HCC, n = 132); 1121
non-cirrhotic patients
affected by ALD or HCV
(HCC, n = 25)
Liver biopsy and US Increased risk of MAFLD-
HCC and alcohol-related
or HCV-related HCC
Thabet et al., 2017 [45] Multi-ethnic Cases only 1101 HBV cases Liver biopsy Hepatic inflammation and
fibrosis stage
Krawczyk et al., 2017 [42] Caucasians Cases only 515 MAFLD cases Liver biopsy (n = 320) Fibrosis stage
Di Sessa et al., 2018 [41] Caucasians Cases only 1002 obese children US and indirect measure-
ment of liver fibrosis
Plasma ALT levels, steatosis
and fibrosis
Krawczyk et al., 2018 [44] Caucasians Cases only 63 MAFLD cases Liver biopsy MAFLD risk
Di Costanzo et al., 2018 [43] Caucasians Cases-control 218 MAFLD cases and 227
controls
US MAFLD presence and
severity
Umano et al., 2018* [87] Multi-ethnic Cases only 860 obese children MRI (n = 490) Steatosis and glucose metab-
olism (only in Caucasians)
Koo et al., 2018 [53] Asians Case-control 416 cases and 109 controls Liver biopsy No evidence of association
Sookoian et al., 2018 [51] Caucasians Case-control 372 cases and 262 controls Liver biopsy No evidence of association
Lin et al., 2018 [55] Asians Cases only 831 obese children US No evidence of association
Basyte-Bacevice et al., 2019
[52]
Caucasians Case-control 462 cases with alcohol or
HCV-related fibrosis and
550 controls
MRI No evidence of association
Xia et al., 2019 [50] Multi-ethnic Meta-analysis 20 studies, including 5415
cases and 17,896 controls
Mixed No evidence of association
Freund et al., 2020 [49] Caucasians Cases only 262 PSC cases Not assessed Liver transplant free survival
Anstee et al., 2020 [54] Caucasians GWAS Discovery: 1483 cases and
17,781 controls;
Validation: 559 cases and
945 controls
Liver biopsy, US No evidence of association
with MAFLD
Teo et al., 2020 [57] Multi-ethnic Meta-analysis 42 studies, including
1047,265 participants
Liver biopsy (n = 8303), MRI Steatosis, MAFLD severity,
fibrosis stage, HCC and
plasma ALT levels
* These associations are referred to the rs626283 polymorphism in theMBOAT7 gene.
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arachidonic acid-containing PC, PS and PE in the liver and an increased
risk of hepatic steatosis onset, due to altered lipid kinetics within hepa-
tocytes, and inflammation [81, 82]. Conversely, the induction of
Mboat5 ameliorates saturated free fatty acid-induced ER stress, lower-
ing also blood glucose and insulin levels in Lepob/ob mice [80, 83]. The
acyltransferase activities of both MBOAT5 and MBOAT7 is susceptible
to inhibition by Thimerosal, a thiol-reactive reagent widely used as a
preservative in several biological and drug product [65] (Fig. 1). This
organomercury compound is the only described reagent that exert a
direct effect on MBOAT5 and MBOAT7.
5. Pathogenic effect of the rs641738 variant and functional
studies
Functional studies aim to decipher the mechanisms through which
inherited risk variants may induce the development of fatty liver and
its progression to more severe forms. In the past years, Sookoian andcoworkers showed that the analysis of the expression of quantitative
trait loci (eQTLs) revealed a correlation between the rs641738 variant
and tissue-specific MBOAT7 expression in liver and fat [51]. Moreover,
Mancina and Dongiovanni have clearly elucidated that the underlying
mechanisms behind the association between the rs641738 variant and
liver damage is related to the hampered hepatic gene and protein
expression of MBOAT7 and not of TMC4, determining changes in PI
species, as further confirmed by Luukkonen et al. [36, 37]. Consistently
with an impaired hepatic MBOAT7 enzymatic activity, patients carry-
ing the T risk allele display changes in plasma and hepatic PI species,
decreasing specifically PI enriched in omega-3 PUFA and arachidonic
acid [36, 37]. In particular, these patients are characterized by lower
concentrations of arachidonoyl-PI/total and in turn, by higher levels of
oleyl-PI/total PI linoleoyl-Pl/total PI ratios (PI containing saturated and
monounsaturated fatty acid chains) [36, 37].
The rs641738 T allele seems to be associated with reduced
MBOAT7 expression in human hepatocytes and in immune cells, but
not in HSCs. Moreover, the polarization of monocytes to both M1 and
Fig. 1. Phosphatidylcholines (PC), Phosphatidylserine (PS), Phosphatidylethanol-
amines (PE) and Phosphatidylinositols (PI) are the main components of the mem-
branes. Phospholipase A2 (cPLA2) releases free arachidonic acid from the sn-2 position
of phospholipids, generating the corresponding lysophospholipids and free arachi-
donic acid. The free arachidonic acid produced may become the precursor of proin-
flammatory mediators (Eicosanoids) or it may be returned to the phospholipid pool
through the activation of an acyl-CoA ligase and either MBOAT7 (that uses lyso-PI) or
MBOAT5 (that uses lyso-PC, lyso-PS, and lyso-PE). Thimerosal, an MBOAT unspecific
inhibitor, increases the production of Eicosanoids (Prostaglandins and Leukotrienes).
Modified by Gijon et al. [65].
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its role in triggering inflammation [72, 84].
The observed reduction of both mRNA and protein synthesis in T
allele carriers seems to be due to the linkage disequilibrium between
the rs641738 variant and those in the 30UTR of MBOAT7 (eg, rs8736
C>T, R2 > 0.95 in the CEU population from the 1000 genomes project),
which may influence mRNA stability/translation [51]. In severely obese
patients, indeed, it has been demonstrated that the rs641738 variation
is in strong linkage disequilibrium with the rs8736 polymorphism
(R2 = 0.98), that show a more close association with MAFLD due to a
stronger MBOAT7 impairment [38]. However, these observations have
been not replicated by Sookoian and colleagues, which demonstrated
that MBOAT7 is down-regulated in MAFLD patients even indepen-
dently of the presence of the rs641738 polymorphism [51].Fig. 2. During fasting or in rs641738 C allele carriers (left panel), MBOAT7 is highly expressed
ond acyl-chain of Lyso-PI, thus guaranteeing their physiological fluidity and the dynamism,
partments. During hyperinsulinemia or in carriers of the T risk allele (right panel), MBOAT7
to TAG synthesis. This process requires the up-regulation of FATP1 and associates in vitro witThis evidence have been further corroborated by an our very recent
paper [72], in which we pointed out that hepatic MBOAT7 down-regu-
lation is a maladaptive response to inherited or diet-induced hyperin-
sulinemia and it causes intracellular fat accumulation in clinical
samples, in in vivo models of MAFLD and in genetically edited HepG2
cells (MBOAT7/). Indeed, in overweight adults, MBOAT7 is hampered
in presence of hyperinsulinemia and severe liver damage, indepen-
dently of the genetic background. This data has been confirmed in
experimental models of MAFLD, in which the reduction of MBOAT7
expression is greater during obesity and hyperinsulinemia. Specifically,
MBOAT7 is physiologically down-regulated during fasting-feeding
cycles in liver, adipose tissue and in intestine and during hyperinsuli-
nemia in vivo, in dependence of insulin signaling activation [85]. Con-
versely, MBOAT5 was up-regulated during hyperinsulinemia,
suggesting that MBOAT7, but not MBOAT5, down-regulation may be
involved in hepatic fat accumulation in metabolic disorders [72]. A
possible link between MBOAT7 and IR has been provided even by
Helsley and colleagues [86], who confirmed a dramatic MBOAT7 sup-
pression during obesity and IR and who correlated its adipose tissue
expression with indices of insulin sensitivity. In keeping with these
findings, Umano and coworkers found an association between lower
degree of whole-body insulin sensitivity and MBOAT7 in obese chil-
dren [87]. Furthermore, it has been demonstrated in Mendelian ran-
domization studies that the ability of a genetic variant to induce IR is
attributable to its impact on the severity of liver damage [33, 88].
In addition, we revealed that MBOAT7 is causally involved in the
pathogenesis of fatty liver. Indeed, acute silencing of hepatic MBOAT7
to levels similar to those observed in carriers of the rs641738 variant
induces hepatic fat accumulation, rapidly leading to steatosis devel-
opment. Moreover, hepatocytes acquire a cell-autonomous property
to accumulate giant lipid droplets when MBOAT7 expression is
impaired. According to this notion, we highlighted that MBOAT7/-
hepatocytes accumulate saturated phospholipids, mainly PI, which
may be delivered to saturated and mono-unsaturated DAG and TAG
synthesis, exacerbating fat deposition (Fig. 2). In line with this data,and it localizes into the membranes, where it conjugates arachidonoyl-CoA to the sec-
that allows the exchange of the metabolites from the membranes to intracellular com-
is reduced, favoring the increase of saturated PI, which are accumulated and delivered
h enhanced de novo lipogenesis. Modified fromMeroni et al., [72].
Fig. 3. Unhealthy dietary habits, excessive caloric intake, high fructose consumption and poor physical exercise are widely recognized as risk factors of IR development. During diet-
induced or pathological hyperinsulinemia, MBOAT7 is hampered in intestine, adipose tissue and in liver. In adipose tissue, peripheral IR, induces MBOAT7 down-regulation and
lipolysis, favoring an exaggerated free fatty acid (FFA) release into the bloodstream. As a consequence, FFAs uptake increases in hepatocytes, even due to the up-regulation of the
fatty acid transporter FATP1. Then, FFAs are stored in intracellular lipid droplets as triglycerides (TAG). Moreover, high insulin concentrations hamper hepatic gene and protein
expression of MBOAT7, determining changes in PI composition pattern, favoring in turn, TAG synthesis and de novo lipogenesis. These events may precipitate hepatic fat deposition
and fatty liver onset. In turn, MBOAT7 down-regulation per semay be causally implicated in fatty liver and in IR exasperation. The impairment in MBOAT7 function may also facili-
tate the switch from simple steatosis to steatohepatitis and fibrosis, affecting lipid composition of the membranes of inflammatory cells and altering lipid mediator profiles. Thus,
the increase amount of free arachidonic acid and its conversion in pro-inflammatory mediators triggers immune cell activation. Cytokine release and hyperinsulinemia may then
stimulate HSCs to produce ECM, perpetuating fibrogenic processes.
6 M. Meroni et al. / EBioMedicine 57 (2020) 102866MBOAT7/ cells display an induction of lipogenic program and a
reduced ability to respond to insulin stimulation through Akt signal-
ling, maybe due to alterations in lipid composition of the membranes.
Helsley et al., supported this hypothesis referring that a reduction of
MBOAT7 expression exacerbates hepatic IR in high fat diet (HFD)-fed
mice and promotes a severe hyperinsulinemia in the fasted state
[86]. It has been demonstrated that enhanced saturation of phospho-
lipids may favor oxidative stress and impair signal transductions
[89]. For instance, the exposure of 3T3-L1 adipocytes to a challenge
of saturated fatty acids may affect insulin sensitivity by hampering
membrane lateral diffusion [90]. The reduced membrane fluidity
influences also the effectiveness of insulin-independent glucose
transporters (GLUTs), impairing glucose uptake [89].
Notwithstanding, the process of fat deposition even requires the
contribution of another player namely fatty acid transporter (FATP1)
and the consequent induction of FFA uptake. Indeed, as MBOAT7 is
also expressed in adipose tissue, we can hypothesize that MBOAT7
down-regulation may promote lipolysis and FFAs release into the cir-
culation, as we revealed in MBOAT7 acutely silenced mice and in T
allele carriers [72]. According to this notion, FATP1 genetic deletion
rescued the intracellular fat accumulation and the increased lipogen-
esis observed in MBOAT7/ hepatocytes. In addition, FATP1 expres-
sion which is inversely related to that of MBOAT7, is independently
associated with the presence of T2D, lipogenesis and inflammation in
obese patients with MAFLD [72].The causative role of MBOAT7 in fatty liver onset has been inde-
pendently confirmed even by Helsley [86], who elegantly evidenced
that Mboat7 loss, but not Tmc4, is sufficient to promote the progres-
sion of NAFLD in the setting of HFD, and then by Tanaka and collabo-
rators, who exploited hepatocyte-specific MBOAT7 KO mice and
MBOAT7-depleted human hepatic cells [91]. These authors revealed
that MBOAT7 KO mice fed HFD spontaneously develop steatosis, and
hepatic fibrosis and that MBOAT7 deficiency favors the formation of
lipid droplets in cultured hepatic cells and in liver spheroids as a con-
sequence of higher TAG synthesis fueled by a non-canonical pathway,
that directly entails the shunting of PI to TAG synthesis [91]. Notwith-
standing, MBOAT7 depletion in 3D-spheroids composed by hepato-
cytes and HSCs, induced cytokines release, fibrogenic markers
expression and collagen deposition [91], due to the accumulation of
the MBOAT7 substrate LPI lipids [86]. Indeed, circulating saturated
LPI were found to be significantly elevated in patients affected by
advanced fibrosis compared to healthy individuals. In turn, LPI
administration may promote hepatic inflammation and fibrosis in
MBOAT7 deficient mice, but not in their wild-type littermates [86].
Notably, this data has been further corroborated by Fondevila et al.,
who revealed that the increased circulating LPI levels in obese NASH
patients, are related to the hepatic over-expression of the G protein-
coupled receptor 55 (GPR55), a putative cannabinoid receptor [92].
Moreover, LPI administration in mice and in cultured cells induced
lipogenic genes and HSCs activation, in a GPR55-dependent manner.
M. Meroni et al. / EBioMedicine 57 (2020) 102866 7Indeed, GPR55 deficiency ameliorated hepatic injuries in mice fed HF,
methionine choline deficient (MCD) diets or injected with carbon tet-
rachloride (CCl4). Taken together, these observations point out that
the restoration of MBOAT7 activity or a reduction of its effectors may
constitute possible therapeutic strategy to improve liver damage in
NAFLD patients [93-95].
6. Conclusion
Several lines of evidence indicate that MBOAT7 may represent a
modifier of liver damage in both genetically or diet-induced MAFLD.
Indeed, it has been made clear that the possible mechanisms behind
the biological association between the rs641738 variant and liver
damage is due to the hampered hepatic gene and protein expression
of MBOAT7 which induces changes in PI composition pattern, favor-
ing in turn TAG synthesis. However, irrespectively of the genetic
background, hyperinsulinemia, a typical feature of metabolic syn-
drome and of post-prandial state, contributes to MBOAT7
impairment, favoring hepatic fat accumulation. These novel observa-
tions may introduce the new concept that MBOAT7 dysfunction may
participate to the cascade of events that may precipitate chronic
hyperinsulinemia to steatosis development (Fig. 3). Moreover,
MBOAT7 impairment may facilitate the progression towards steato-
hepatitis and fibrosis, profoundly affecting lipid composition of the
membranes and altering lipid mediator profiles. Therefore, this,
surely, constitutes a new example of gene-environment interaction,
which should be deeply explored in future studies.
7. Outstanding questions
Nowadays, TAG accumulated in lipid droplets are not considered
as just ‘innocent bystander’, but real culprits of the cellular injuries
[96]. Indeed, emerging evidence pinpoints the role of lipid droplets in
the multiple processes that leading to steatohepatitis [96, 97]. They
are enormously dynamic, modifying their location, size, lipid and
protein composition in response to environmental stimuli. Thus, they
are engaged not only in energy expenditure but also in signaling
pathways, acting as hubs that integrate metabolic and inflammatory
processes [97]. The deep understanding of the biological implication
of changes in lipid composition may be useful to narrow the gap in
the knowledge of MAFLD pathogenesis.
We are aware that in the complex architecture of MAFLD, several
other contributors may participate to fatty liver onset. We are also
conscious that further studies are required to better explain how IR
may lead to liver damage. Thus, it should be useful to better address
the impact of the rs641738 variation on hepatic disorders and the
mechanisms entailing MBOAT7 down-regulation in IR-induced liver
injuries. In the future, researches aimed to identify therapeutic
approaches that influence MBOAT7 activity might represent a novel
targeted strategy in the management of patients with MAFLD and in
particular in those with diabetes. Furthermore, the effects of
rs641738 variant and MBOAT7 alterations on MetS components, cir-
culating lipids and cardiovascular risk remain uncharted.
8. Search strategy and selection criteria
Data for this Review were identified by searches of MEDLINE and
PubMed, and references from relevant articles using the search terms
“LPIAT1”, “MBOAT7”, “MAFLD”, “NAFLD”,“NASH” and “rs641738”.
Reports from meetings were not included. Only articles published in
English between 2000 and 2020 were included.
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